Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Ernst, Thomas, Chase, Andrew J, Score, Joannah, Hidalgo-Curtis, Claire E, Bryant, Catherine, Jones, Amy V, Waghorn, Katherine, Zoi, Katerina +10 more·2010·Nature Genetics
DOI 10.1038/ng.621

Cited by (1,000)

Items 201–300 of 1,000

  1. Early Steps of Follicular Lymphoma Pathogenesis
    Sandrine Roulland, Mustapha Faroudi, Émilie Mamessier, Stéphanie Sungalee, Gilles Salles, Bertrand Nadel · 2011 · Advances in immunology
  2. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma
    Rajat Banerjee, Ram Shankar Mani, Nickole Russo, Christina Springstead Scanlon, Alex Tsodikov, Xiaojun Jing, Qi Cao, Nallasivam Palanisamy, T Metwally, Ronald C. Inglehart et al. · 2011 · Oncogene
  3. Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain
    Stephen Antonysamy, Bradley Condon, Zhanna Druzina, J.B. Bonanno, T. Gheyi, Feiyu Zhang, Iain J. MacEwan, Aiping Zhang, Sheela Ashok, Logan A. Rodgers et al. · 2013 · PLoS ONE
  4. Genetic abnormalities and pathophysiology of MDS
    Naoko Hosono · 2019 · International Journal of Clinical Oncology
  5. The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review
    Hope S. Rugo, Ira Allen Jacobs, Shikhar Sharma, Frank A. Scappaticci, Thomas A. Paul, Kristen Jensen-Pergakes, Gabriel G. Malouf · 2020 · Advances in Therapy
  6. Retraction Note: Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease
    Antonio Herrera-Merchan, Lorena Arranz, Jose Manuel Ligos, Antonio de Molina-Iracheta, Orlando Domı́nguez, Susana González · 2017 · Nature Communications · Retracted
  7. The Epigenetic Landscape of Acute Myeloid Leukemia
    Emma Conway O’Brien, Steven M. Prideaux, Timothy J. T. Chevassut · 2014 · Advances in Hematology
  8. Histone-Modifying Enzymes: Regulators of Developmental Decisions and Drivers of Human Disease
    Jill S. Napierala, Evangelia Koutelou, Andria C Schibler, Sharon Dent · 2012 · Epigenomics
  9. Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape
    Fan Liu, Lan Wang, Fabiana Perna, Stephen D. Nimer · 2016 · Nature reviews. Cancer
  10. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2 -V617F
    Pontus Lundberg, Hitoshi Takizawa, Lucia Kubovčáková, Guoji Guo, Hui Hao-Shen, Stephan Dirnhofer, Stuart H. Orkin, Markus Gabriel Manz, Radek C. Skoda · 2014 · The Journal of Experimental Medicine
  11. Frequent deletions of <i>JARID2</i> in leukemic transformation of chronic myeloid malignancies
    Puda, Ana, Milosevic, Jelena D., Berg, Tiina, Klampfl, Thorsten, Harutyunyan, Ashot S., Gisslinger, Bettina, Rumi, Elisa, Pietra, Daniela, Malcovati, Luca, Elena, Chiara et al. · 2012 · American Journal of Hematology
  12. EZH2 in normal hematopoiesis and hematological malignancies
    Laurie Herviou, Giacomo Cavalli, Guillaume Cartron, Bernard Klein, Jérôme Moreaux · 2015 · Oncotarget
  13. Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis
    Stanley Chun-Wei Lee, Sarah Miller, Craig D. Hyland, Maria Kauppi, Marion Lebois, Ladina Di Rago, Donald Metcalf, Sarah Kinkel, Emma C. Josefsson, Marnie E. Blewitt et al. · 2015 · Blood
  14. EZH2: Not EZHY (Easy) to Deal
    Gauri Deb, Anup Kumar Singh, Sanjay Gupta · 2014 · Molecular Cancer Research
  15. Epigenomics of leukemia: from mechanisms to therapeutic applications
    Cristina Florean, Michaël Schnekenburger, Cindy Grandjenette, Mario A. Dicato, Marc F. Diederich · 2011 · Epigenomics
  16. Mutations of myelodysplastic syndromes (MDS): An update
    Bani Bandana Ganguly, Nitin N. Kadam · 2016 · Mutation Research/Reviews in Mutation Research
  17. Emerging EZH2 Inhibitors and Their Application in Lymphoma
    Jennifer Kimberly Lue, Jennifer Effie Amengual · 2018 · Current Hematologic Malignancy Reports
  18. Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas
    Matthew Alexander Lunning, M R Green · 2015 · Blood Cancer Journal
  19. Involvement of long noncoding RNAs in diseases affecting the central nervous system
    Pastori, Chiara, Wahlestedt, Claes · 2012 · RNA Biology
  20. Pathogenesis and Consequences of Uniparental Disomy in Cancer
    Hideki Makishima, Jaroslaw Pawel Maciejewski · 2011 · Clinical Cancer Research
  21. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
    Tariq I. Mughal, Nicholas C.P. Cross, E. Padron, Ramon Velasquez Tiu, Michael Robert Savona, Luca Malcovati, Raoul Tibes, Rami S. Komrokji, Jean‐Jacques Kiladjian, Gullermo Garcia-Manero et al. · 2015 · Haematologica
  22. The noncanonical role of EZH2 in cancer
    Jinhua Huang, Hongwei Gou, Jia Yao, Kaining Yi, Zhigang Jin, Masao Matsuoka, Tiejun Zhao · 2021 · Cancer Science
  23. Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression
    Lukas D. Wartman, David E. Larson, Zhifu Xiang, Li Ding, Ken Chen, Ling Lin, Patrick Cahan, Jeffery M. Klco, John Sutton Welch, Cheng Li et al. · 2011 · Journal of Clinical Investigation
  24. Orchestration of H3K27 methylation: mechanisms and therapeutic implication
    Mei‐Ren Pan, Ming‐Chuan Hsu, Li‐Tzong Chen, Wen‐Chun Hung · 2017 · Cellular and Molecular Life Sciences
  25. Transcriptional regulation of cellular senescence
    Lanigan, F, Geraghty, J G, Bracken, A P · 2011 · Oncogene
  26. EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells
    Bettina Fussbroich, Nina Wagener, Stephan Macher‐Goeppinger, Axel Benner, Maria Fälth, Holger Sültmann, Angela Holzer, Karin Hoppe‐Seyler, Felix Hoppe‐Seyler · 2011 · PLoS ONE
  27. Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2
    Huafeng Xie, Cong Peng, Jialiang Huang, Bin E. Li, Woojin Kim, Elenoe C. Smith, Yuko Fujiwara, Jun Qi, Giulia Cheloni, Partha Pratim Das et al. · 2016 · Cancer Discovery
  28. Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
    Jiro Kikuchi, Daisuke Koyama, Taeko Wada, Tohru Izumi, Peter Olaf Hofgaard, Bjarne Bogen, Yusuke Furukawa · 2015 · Journal of Clinical Investigation
  29. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm
    Yue Yang, Hajime Akada, Dipmoy Nath, R. Hutchison, Golam Mohi · 2016 · Blood
  30. Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis
    Teng Gao, Ryan N. Ptashkin, Kelly L. Bolton, Maria Sirenko, Christopher Fong, Barbara G. Spitzer, Kamal N. Menghrajani, Juan Arango Ossa, Yangyu Zhou, Elsa Bernard et al. · 2021 · Nature Communications
  31. JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment
    Alessandro Maria Vannucchi, Lisa Pieri, Paola Guglielmelli · 2010 · Therapeutic Advances in Hematology
  32. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome
    T-C Chen, H-A Hou, W-C Chou, J-L Tang, Y-Y Kuo, C-Y Chen, M-H Tseng, C-F Huang, Y-J Lai, Y-C Chiang et al. · 2014 · Blood Cancer Journal
  33. Molecular Pathways: Deregulation of Histone H3 Lysine 27 Methylation in Cancer—Different Paths, Same Destination
    Teresa Ezponda, Jonathan D. Licht · 2014 · Clinical Cancer Research
  34. Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
    John O Mascarenhas, Tariq I. Mughal, Srđan Verstovšek · 2012 · Current Medicinal Chemistry
  35. How I treat polycythemia vera
    Francesco Passamonti · 2012 · Blood
  36. Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension
    Malik Bisserier, Prabhu Mathiyalagan, Shihong Zhang, Firas Elmastour, Peter Dorfmüller, Marc J.C. Humbert, Gregory David, Sima T. Tarzami, Thomas Weber, Frédéric Perros et al. · 2021 · Circulation
  37. The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Connie A. Larsson, Gilbert J. Cote, Alfonso Quintás‐Cardama · 2013 · Molecular Cancer Research
  38. Emerging concepts of epigenetic dysregulation in hematological malignancies
    Panagiotis Ntziachristos, Omar Ibrahim Abdel-Wahab, Iannis Aifantis · 2016 · Nature Immunology
  39. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states
    Tim J. Wigle, Sarah K. Knutson, Lei Jin, Kevin W. Kuntz, Roy M. Pollock, Victoria M. Richon, Robert A. Copeland, Margaret Porter Scott · 2011 · FEBS Letters
  40. Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy
    Amir T. Fathi, Omar Ibrahim Abdel-Wahab · 2011 · Advances in Hematology
  41. The enigma of monosomy 7
    Toshiya Inaba, Hiroaki Honda, Hirotaka Matsui · 2018 · Blood
  42. Whole Exome Sequencing Identifies Novel Recurrently Mutated Genes in Patients with Splenic Marginal Zone Lymphoma
    Marina Parry, Matthew J.J. Rose-Zerilli, Jane Gibson, Sarah Ennis, Renata J. Walewska, Jade Forster, Helen Parker, Zadie A. Davis, Anne Catherine Gardiner, Andrew R Collins et al. · 2013 · PLoS ONE
  43. Molecular Pathophysiology of Myelodysplastic Syndromes
    Lindsley, R. Coleman, Ebert, Benjamin L. · 2013 · Annual Review of Pathology: Mechanisms of Disease
  44. Epigenetics of myelodysplastic syndromes
    Raphaël Itzykson, Pierre Fenaux · 2013 · Leukemia
  45. EZH2 as a potential target in cancer therapy
    Michael T. McCabe, Caretha L. Creasy · 2014 · Epigenomics
  46. Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression
    Nienke A. de Vries, Danielle Hulsman, Waseem Akhtar, Johann de Jong, Denise C. Miles, Marleen Blom, Olaf van Tellingen, Jos Jonkers, Maarten van Lohuizen · 2015 · Cell Reports
  47. Driver mutations in acute myeloid leukemia
    Ashwin Kishtagari, Ross L. Levine, Aaron D. Viny · 2020 · Current Opinion in Hematology
  48. Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis
    Jaclyn Andricovich, Kai Yan, Weiqun Peng, Adlen Foudi, Alexandros Tzatsos · 2016 · Journal of Clinical Investigation
  49. Understanding of leukemic stem cells and their clinical implications
    Xuefei Wang, Shile Huang, Ji‐Long Chen · 2017 · Molecular Cancer
  50. Nonsense-mediated RNA decay and its bipolar function in cancer
    Gonçalo Nogueira, Rafael Oliveira Fernandes, Juan F. García-Moreno, Luı́sa Romão · 2021 · Molecular Cancer
  51. Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
    Xuejiao Tian, Sai‐Yang Zhang, Hong‐Min Liu, Yanbing Zhang, Christopher Blair, Dan Mercola, Paolo Sassone‐Corsi, Xiaolin Zi · 2013 · Current Cancer Drug Targets
  52. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer
    Mahara, Sylvia, Lee, Puay Leng, Feng, Min, Tergaonkar, Vinay, Chng, Wee Joo, Yu, Qiang · 2016 · Proceedings of the National Academy of Sciences
  53. Context-dependent actions of Polycomb repressors in cancer
    Martijn A. J. Koppens, Maarten van Lohuizen · 2015 · Oncogene
  54. Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
    Hye Jung Kim, Harvey Cantor, Kat Cosmopoulos · 2020 · Trends in Immunology
  55. The evolving genomic landscape of myeloproliferative neoplasms
    Jyoti Nangalia, Tony R. Green · 2014 · Hematology
  56. Recruitment and Biological Consequences of Histone Modification of H3K27me3 and H3K9me3
    Jeong Hyun Kim, Hye‐Jin Kim · 2012 · ILAR Journal
  57. EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner
    Suresh Bugide, Romi Gupta, Michael R. Green, Narendra Wajapeyee · 2021 · Proceedings of the National Academy of Sciences
  58. Multifaceted role of EZH2 in breast and prostate tumorigenesis
    Gauri Deb, Vijay S. Thakur, Sanjay Gupta · 2013 · Epigenetics
  59. Perspective in Alternative Splicing Coupled to Nonsense-Mediated mRNA Decay
    Juan F. García-Moreno, Luı́sa Romão · 2020 · International Journal of Molecular Sciences
  60. Epigenetics in the hematologic malignancies
    Chun Yew Fong, Jessica Morison, Mark A. Dawson · 2014 · Haematologica
  61. Weaver Syndrome‐Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro
    Ana S.A. Cohen, Damian Yap, M. E. Suzanne Lewis, Chieko Chijiwa, María A. Ramos‐Arroyo, Natália Tkachenko, Valentina Milano, Mélanie Fradin, Margaret L. McKinnon, Katelin N. Townsend et al. · 2015 · Human Mutation
  62. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
    Daphné Morel, Geneviève Almouzni, Jean‐Charles Soria, Sophie C. Postel-Vinay · 2016 · Annals of Oncology
  63. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution
    Chien‐Chin Lin, Hsin‐An Hou, Wen‐Chien Chou, Yuan‐Yeh Kuo, Chieh‐Yu Liu, Chien‐Yuan Chen, Yan-Jun Lai, Mei‐Hsuan Tseng, Chi‐Fei Huang, Ying‐Chieh Chiang et al. · 2013 · American Journal of Hematology
  64. Assay Development for Histone Methyltransferases
    Kurumi Y. Horiuchi, Mia M. Eason, Joseph J. Ferry, Jamie L. Planck, Colin P. Walsh, Robert Frank Smith, Konrad T. Howitz, Haiching Ma · 2013 · Assay and Drug Development Technologies
  65. Targeting histone methyltransferase EZH2 as cancer treatment
    Y. Kondo · 2014 · The Journal of Biochemistry
  66. DNA Methylation Signature for EZH2 Functionally Classifies Sequence Variants in Three PRC2 Complex Genes
    Sanaa Choufani, William T. Gibson, Andrei L. Turinsky, Brian Hon‐Yin Chung, Tianren Wang, Kopal Garg, Alessandro Vitriolo, Ana S.A. Cohen, Sharri S. Cyrus, Sarah J. Goodman et al. · 2020 · The American Journal of Human Genetics
  67. Epigenomics of cancer – emerging new concepts
    Melanie R. Hassler, Gerda Egger · 2012 · Biochimie
  68. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis
    Tobias Berg, Silvia Thoene, Damian Yap, Tracee Wee, Nathalie Schoeler, Patty Rosten, Emilia L. Lim, Misha Bilenky, Andrew J. J. Mungall, Thomas Oellerich et al. · 2014 · Blood
  69. Cancer Epigenetics: New Therapies and New Challenges
    Eleftheria ChR. Hatzimichael, Tim Crook · 2013 · Journal of Drug Delivery
  70. PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN
    Friederike Pastore, Neha Bhagwat, Alessandro Pastore, Aliaksandra Radzisheuskaya, Abdul Karzai, Aishwarya Krishnan, Bing Li, Robert L. Bowman, Wenbin Xiao, Aaron D. Viny et al. · 2020 · Cancer Discovery
  71. Ezh2 Inhibition by Tazemetostat: Mechanisms of Action, Safety and Efficacy in Relapsed/refractory Follicular Lymphoma
    Edith Julia, Gilles Salles · 2021 · Future Oncology
  72. TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia
    Cristina Pérez, Nicolás Martínez‐Calle, José Ignacio Martín-Subero, Víctor Segura, Éric Delabesse, Marta Fernández‐Mercado, Leire Gárate, Sara Álvarez, J. Rifón, Sara Varea et al. · 2012 · PLoS ONE
  73. PRC2‐complex related dysfunction in overgrowth syndromes: A review of EZH2 , EED , and SUZ12 and their syndromic phenotypes
    Sharri S. Cyrus, Deepika D’Cunha Burkardt, David D. Weaver, William T. Gibson · 2019 · American Journal of Medical Genetics Part C Seminars in Medical Genetics
  74. Non‐coding RNAs and EZH2 interactions in cancer: Long and short tales from the transcriptome
    Leonidas Benetatos, Evangelos Voulgaris, George Vartholomatos, Eleftheria ChR. Hatzimichael · 2012 · International Journal of Cancer
  75. Chromatin modifiers and the promise of epigenetic therapy in acute leukemia
    Sarah M. Greenblatt, S. Nimer · 2014 · Leukemia
  76. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome
    Sergey I. Nikolaev, Federico Andrea Santoni, Anne Vannier, Emilie Falconnet, Emanuela Giarin, Giuseppe Basso, Alexander Hoischen, Joris Andre Veltman, Jürgen Groet, Dean Nižetić et al. · 2013 · Blood
  77. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome
    Syed A. Mian, Alexander Smith, Austin Gladston Kulasekararaj, Aytug Kizilors, A. M. Mohamedali, N C Lea, Costas Mitsopoulos, K. Ford, Erick E Nasser, Thomas Seidl et al. · 2013 · Haematologica
  78. Overgrowth Syndromes
    Andrew C. Edmondson, Jennifer M. Kalish · 2015 · Journal of Pediatric Genetics
  79. Genetic and epigenetic alterations of myeloproliferative disorders
    Jelena D. Milosevic Feenstra, Róbert Královics · 2012 · International Journal of Hematology
  80. Diagnostic Applications of High-Throughput DNA Sequencing
    Scott Dexter Boyd · 2012 · Annual Review of Pathology Mechanisms of Disease
  81. The role of alternative splicing coupled to nonsense-mediated mRNA decay in human disease
    Paulo J. da Costa, Juliane Menezes, Luı́sa Romão · 2017 · The International Journal of Biochemistry & Cell Biology
  82. Myelofibrosis in 2019: moving beyond JAK2 inhibition
    Michael Schieber, John D. Crispino, Brady Lee Stein · 2019 · Blood Cancer Journal
  83. Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
    Hsin‐An Hou, Hwei‐Fang Tien · 2020 · Journal of Biomedical Science
  84. The NSD1 and EZH2 Overgrowth Genes, Similarities and Differences
    Katrina Tatton‐Brown, Nazneen Rahman · 2013 · American Journal of Medical Genetics Part C Seminars in Medical Genetics
  85. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia
    Brenton G. Mar, Lars Bullinger, Ellen M. Basu, Krysta D. Schlis, L B Silverman, Konstanze Döhner, Scott A. Armstrong · 2012 · Leukemia
  86. Targeting epigenetic regulations in cancer
    Bo Ning, Wenyuan Li, Wei Zhao, Rong‐Fu Wang · 2015 · Acta Biochimica et Biophysica Sinica
  87. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome
    Huai-Hsuan Huang, Fei Chen, Wen-Chien Chou, H. Hou, B. Ko, Chien-Ting Lin, Jih-Luh Tang, C. Li, M. Yao, W. Tsay et al. · 2019 · BMC Cancer
  88. Quantitative Assessment of Chromatin Immunoprecipitation Grade Antibodies Directed against Histone Modifications Reveals Patterns of Co-occurring Marks on Histone Protein Molecules
    Sally E. Peach, Emily L. Rudomin, Namrata D. Udeshi, Steven A. Carr, Jacob D. Jaffe · 2012 · Molecular & Cellular Proteomics
  89. Polycomb/Trithorax Antagonism: Cellular Memory in Stem Cell Fate and Function
    Marjorie Brand, Kiran Kumar Nakka, Jiayu Zhu, Francis Jeffrey Dilworth · 2019 · Cell stem cell
  90. Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside
    Justin L. Korfhage, David B. Lombard · 2019 · Molecular Cancer Research
  91. Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
    on behalf of AGIMM investigators, Elena Tenedini, Isabella Bernardis, Valentina Artusi, Lucia Artuso, Enrica Roncaglia, Paola Guglielmelli, Lisa Pieri, Costanza Bogani, Flavia Biamonte et al. · 2013 · Leukemia
  92. Epigenetic Factors in Cancer Development: Polycomb Group Proteins
    Andrea Piunti, Diego Pasini · 2010 · Future Oncology
  93. CURLY LEAF Regulates Gene Sets Coordinating Seed Size and Lipid Biosynthesis
    Jun Liu, Shulin Deng, Huan Wang, Jian Ye, Hui‐Wen Wu, Hai‐Xi Sun, Nam‐Hai Chua · 2016 · PLANT PHYSIOLOGY
  94. MicroRNAs Overcome Cell Fate Barrier by Reducing EZH2-Controlled REST Stability during Neuronal Conversion of Human Adult Fibroblasts
    Seong Won Lee, Young Mi Oh, Ya-Lin Lu, Woo Kyung Kim, Andrew S.J. Yoo · 2018 · Developmental Cell
  95. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms
    Anouk Emadali, Neda Hoghoughi, Samuel Duley, Azadeh Hajmirza, Els Verhoeyen, François‐Loïc Cosset, Philìppe Bertrand, Christophe Roumier, Anne Roggy, Céline Suchaud-Martin et al. · 2016 · Blood
  96. H3 K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations
    Bernhard Lehnertz, Yu Wei Zhang, Isabel Boivin, Nadine Mayotte, Elisa Tomellini, Jalila Chagraoui, Vincent‐Philippe Lavallée, Josée Hébert, Guy Sauvageau · 2017 · Blood
  97. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia
    Tun Kiat Ko, Asif Javed, Kian Leong Lee, Thushangi N. Pathiraja, Xingliang Liu, Simeen Malik, Sheila Xinxuan Soh, Xiu Ting Heng, Naoto Takahashi, Joanna Hui Juan Tan et al. · 2020 · Blood
  98. Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia
    Meng Li, Roxane Collins, Yuchen Jiao, Peter D. Ouillette, Dale Lee Bixby, Harry Paul Erba, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Sami N. Malek · 2011 · Blood
  99. Genes encoding members of the JAK ‐ STAT pathway or epigenetic regulators are recurrently mutated in T‐cell prolymphocytic leukaemia
    Cristina López, Anke Katharina Bergmann, Ulrike Paul, Eva Maria Murga Penas, Inga Nagel, Matthew J. Betts, Patricia Johansson, Matthias Ritgen, Tycho Baumann, Marta Aymerich et al. · 2016 · British Journal of Haematology
  100. Symphony of epigenetic and metabolic regulation—interaction between the histone methyltransferase EZH2 and metabolism of tumor
    Tengrui Zhang, Yueqing Gong, Hui Meng, Chen Li, Lixiang Xue · 2020 · Clinical Epigenetics